Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,795 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final Survival Analysis of ROSE/TRIO-012.
Mackey JR, McCarthy N, Gelmon KA, Verma S, Fresco R, Thireau F, Fung H, Martín M. Mackey JR, et al. Among authors: martin m. J Clin Oncol. 2016 Oct 20;34(30):3714-3715. doi: 10.1200/JCO.2016.68.9182. J Clin Oncol. 2016. PMID: 27480148 No abstract available.
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Hugh J, et al. Among authors: martin m. J Clin Oncol. 2009 Mar 10;27(8):1168-76. doi: 10.1200/JCO.2008.18.1024. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204205 Free PMC article.
TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.
Mackey J, Gelmon K, Martin M, McCarthy N, Pinter T, Rupin M, Youssoufian H. Mackey J, et al. Among authors: martin m. Clin Breast Cancer. 2009 Nov;9(4):258-61. doi: 10.3816/CBC.2009.n.044. Clin Breast Cancer. 2009. PMID: 19933083 Clinical Trial.
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Valero V, et al. Among authors: martin m. J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29. J Clin Oncol. 2011. PMID: 21115860 Clinical Trial.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiełło-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Baños A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR; TRIO 010 investigators. Martin M, et al. Lancet Oncol. 2011 Apr;12(4):369-76. doi: 10.1016/S1470-2045(11)70037-7. Epub 2011 Mar 21. Lancet Oncol. 2011. PMID: 21429799 Clinical Trial.
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Eiermann W, et al. Among authors: martin m. J Clin Oncol. 2011 Oct 10;29(29):3877-84. doi: 10.1200/JCO.2010.28.5437. Epub 2011 Sep 12. J Clin Oncol. 2011. PMID: 21911726 Clinical Trial.
12,795 results
You have reached the last available page of results. Please see the User Guide for more information.